“…CDCP1, a single-channel transmembrane protein, 4 is overexpressed in NSCLC and is significantly associated with poor prognosis in patients. 5 , 6 , 7 , 8 In malignant tumor cells, CDCP1 can be activated by Src kinase, which promotes the proliferation, invasion, and metastasis of tumor cells through classic signaling pathways such as MAPK (Ras/ERK) and PI3K/AKT. 9 , 10 , 11 , 12 , 13 Besides, numerous studies have demonstrated that antibodies targeting CDCP1, including MAB41-2, MAB10-D7, and C20Fc, can inhibit tumor growth and metastasis in various animal models and improve the efficacy of chemotherapy drugs.…”